



DATE OF ANNUAL GENERAL MEETING

28 September 2026, Adelaide, Australia: Mayne Pharma Group Limited (Mayne Pharma or the Company) (ASX: MYX) advises that, in accordance with ASX Listing Rule 3.13.1, its 2026 Annual General Meeting (AGM) will be held at 10.00am (AEDT, Sydney time) on Friday 20 November 2026.

The closing date for receipt of nominations from persons wishing to be considered for election as a director is Friday 2 October 2026. Any nominations must be received in writing no later than 5.00pm (AEDT) on Friday 2 October 2026 at the Company's registered office, 1538 Main North Road, Salisbury South, South Australia 5106.

Shareholders will be advised of further details regarding the AGM, including the venue and arrangements for participation, in a separate Notice of Meeting, which will be provided to shareholders in due course. The Notice of Meeting will also be available on the ASX Company Announcements Platform and the Company's website at maynepharma.com.

Click [here](#) to view this announcement on Mayne Pharma's Investor Hub.

- ENDS -

For further information contact:

Dr Tom Duthy
Investor Relations
+61 402 493 727
ir@maynepharma.com

Authorised for release to the ASX by the Board Chair.

Follow us on [LinkedIn](#)

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women's health in the United States and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.

